Welcome to the e-CCO Library!

DOP87: Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Magro, F.(1);De Hertogh, G.(2);Protic, M.(3);Chan, L.S.(3);Pollack, P.(3);Feagan, B.G.(4);Harpaz, N.(5);Pai, R.(6);Reinisch, W.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP87: Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: D'Amico, F.(1);Fiorino, G.(1);Massarini, E.(1);Solitano, V.(1);Guillo, L.(2);Allocca, M.(1);Furfaro, F.(3);Zilli, A.(3);Bonovas, S.(1);Peyrin-Biroulet, L.(4);Danese, S.(5)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP87: Multi-parameter datasets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G-R. Jones*1,2, M. Lyons2, N. Plevris1, P. Jenkinson1, C. Bisset1, J. Fulforth1, C. S. Chuah1, S. Minnis1, S-L. Gillespie1, W. Brindle1, C. Burgess3, P. Henderson3, D. Wilson3, C. Lees1

Created: Friday, 22 February 2019, 9:41 AM
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Feagan , B.G.(1)*;Sands , B.(2);Siegel , C.A.(3);Dubinsky , M.(4);Longman , R.(5);Sabinho , J.(6);Laurent , O.(7);Luo , A.(7);Lu, JD.(7);Nguyen, D.(7);Towfic , F.(7);DuVall, A.(8);Woyranowski , M.(9);Al Kharrat , H.(10);McGovern, D.P.B.(11);
Created: Friday, 14 July 2023, 10:43 AM
DOP88 Visceral fat area correlates well with anti-TNFα drug levels and secondary loss of response in Crohn’s disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Z. Lim1, C. Welman2, W. Raymond3, L. Thin1,3

Created: Thursday, 30 January 2020, 10:12 AM
DOP88: Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials
Year: 2021
Source: ECCO'21 Virtual
Authors: Peyrin-Biroulet, L.(1);Louis, E.(2);Ghosh, S.(3);Lee, S.D.(4);Griffith, J.(5);Wallace, K.(5);Berg, S.(5);Loftus Jr, E.V.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP88: Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTE
Year: 2022
Source: ECCO'22
Authors: Bello, F.(1);Lördal, M.(2);Johansson, F.(3);Sabhan, H.(4);Muhsen, S.(2);Borin, A.(5);Forsberg, O.(6);Wennerström, C.(6);Söderman, C.(4);Almer, S.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP88: Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in inflammatory bowel disease patients: a nationwide Danish cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. B. Thomsen*1, K. H. Allin2, J. Burisch2, C. B. Jensen2, S. Hansen2, L. L. Gluud1, K. Theede1, M. Kiszka-Kanowitz1, A. M. Nielsen1, T. Jess2

Created: Friday, 22 February 2019, 9:41 AM
DOP88: Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lin, S.(1,2)*;Hannon, E.(3);Waring, J.F.(4);Reppell, M.(4);Smaoui, N.(4);Pivorunas, V.L.(4);Guay, H.(4);Chanchlani, N.(1,2);Bewshea, C.(2);Bai, B.Y.H.(5,6);Kennedy, N.A.(1,2);Goodhand, J.R.(1,2);Mill, J.(3);Ahmad, T.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Haberman Ziv1, P. Minar1, R. Karns1, P. Dexheimer1, S. Ghandikota1, S. Tegge1, D. Shapiro1, B. Shuler1, S. Venkateswaran2, T. Braun3, B. Aronow1, G. Gibson4, J. Hyams5, S. Kugathasan2, A. Jegga1, L. Denson1, CCF sponsored RISK Study

Created: Thursday, 30 January 2020, 10:12 AM
DOP89: Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Zoller, H.(1);Wolf, M.(2);Blumenstein, I.(3);Primas, C.(4);Lindgren, S.(5);Thomsen, L.L.(6);Reinisch, W.(4);Iqbal, T.(7)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP89: Final growth in paediatric Crohn's disease is impaired also in the era of biologics: a population-based analysis from the epiIIRN administrative cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Assa1, S. Cohen2, N. Asayag*3, N. Dan4, G. Focht4, O. Ledder4, N. Lederman5, E. Matz6, A. Cahan7, R. Balicer8, B. Feldman8, I. Brufman8, D. Turner4

Created: Friday, 22 February 2019, 9:41 AM
DOP89: Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fumery, M.(1)*;Nancey, S.(2);Nachury, M.(3);Allez, M.(4);Rouillon, C.(5);Boureille, A.(6);Altwegg, R.(7);Serrero, M.(8);Vuitton, L.(9);Bouguen, G.(10);Abitbol, V.(11);Boualit, M.(12);Biron, A.(13);Panis, Y.(14);Laharie, D.(15);Amiot, A.(16);Simon, M.(17);Caillo, L.(18);Hébuterne, X.(19);Vidon, M.(20);Benezech, A.(21);Elgharabawy , Y.(22);Peyrin-biroulet, L.(23);
Created: Friday, 14 July 2023, 10:43 AM
DOP89: Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Wang, Z.(1);Kantasiripitak, W.(1);Verstockt, B.(2,3);João, S.(2,3);Ferrante, M.(2,3);Declerck, P.(1);D’Haens, G.(4);Laharie, D.(5);Vermeire, S.(2,3);Dreesen, E.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP90 The role of Nlrp9b, a novel NLR member in regulating experimental colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Zheng1,2, M. Levy1, E. Elinav1

Created: Thursday, 30 January 2020, 10:12 AM
DOP90: Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Vermeire, S.(2);D'Haens, G.R.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Le Bars, M.(8);Lahaye , M.(9);Nazar, M.(10);Ni, L.(11);Bravatà , I.(12);Lavie , F.(9);Daperno , M.(13);Lukáš , M.(14);Armuzzi , A.(15);Löwenberg , M.(3);Gaya , D.R.(16);Danese , S.(17); STARDUST
Created: Friday, 11 February 2022, 3:52 PM
DOP90: Physician global assessment of IBD Activity is associated with COVID-19 severity in patients aged less than 50 years
Year: 2021
Source: ECCO'21 Virtual
Authors: Ricciuto, A.(1);Lamb, C.(2,3);Benchimol, E.I.(1);Walker, G.(4);Kennedy, N.(5,6);Kuenzig, M.E.(1);Kaplan, G.(7);Griffiths, A.M.(1);Reinisch, W.(8);Sebastian, S.(9,10)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP90: The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;Sapin, C.(2);Chan-Diehl, F.W.(3);Moses, R.E.(3);Siegmund, B.(4);Walsh, A.(5);Kobayashi, T.(6);Parambir, D.S.(7);Travis, S.(8);
Created: Friday, 14 July 2023, 10:43 AM
DOP90: The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD: results after 20 years of follow-up in the IBSEN study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Ossum*1,2, Ø. Palm3, M. Cvancarova4, B. Moum1,2, M. L. Høivik1, The IBSEN study group1

Created: Friday, 22 February 2019, 9:41 AM
N001: Developing a quality of life score for Crohn’s anal fistula (CAF-QoL)
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Adegbola1*, L. Dibley2,3, K. Sahnan1, P. Tozer1,4, N. Yassin1,5, T. Wade2, A. Verjee6, R. Sawyer7, S. Mannick7, P. Lung1,8, R. Phillips1, O. Faiz1,4, J. Warusavitarne1,4, A. Hart1,9, C. Norton2

Created: Thursday, 21 February 2019, 9:14 AM